CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
(Santa Clara, Calif., November 21, 2017) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers:
Petersonet al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model
- PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model
The FATZO model mirrors human disease conditions by providing polygenic obesity and metabolic patterns of hyperglycemia and hyperinsulinemia to support insulin resistance similar to the metabolic disease in patients with insulin resistance / type 2 diabetes.
“Crown Bioscience is committed to validating the translatability of our models and providing novel scientific advancements that are representative of human conditions of obesity and type 2 diabetes.” said Jim Wang Sr. Vice President, Cardiovascular Metabolic Research, Crown Bioscience. “Our innovations will continue to enable breakthroughs for preclinical drug discovery and development.”
For more information on Crown Bioscience’s commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...
Crown Bioscience Enters Global Agreement with Shanghai Model Organisms Center
Crown Bioscience announces the completion of a global collaboration agreement with the Shanghai Model Organism Center (SMOC). This five-year agreement extends the existing partnership and will prov...
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.